Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    47,934.17
    -1,138.59 (-2.32%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Global Stem Cell Therapy Market to Reach $242.3 Million by 2027

·26-min read

Abstract: - Global Stem Cell Therapy Market to Reach $242. 3 Million by 2027. - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127. 5 Million in the year 2020, is projected to reach a revised size of US$242.

New York, May 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW
3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR
- The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

- Select Competitors (Total 33 Featured) -

  • Advanced Cell Technology

  • Anterogen, Ltd.

  • Biotime, Osiris Therapeutics

  • Cynata

  • Cytori Therapeutics

  • HolostemTerapieAvanzateS.r.l.

  • Human Longevity

  • JCR Pharmaceuticals

  • Medipost

  • Mesoblastand AlloSource

  • NuVasive

  • Osiris Therapeutics, Inc.

  • Pharmicell

  • Promethera Biosciences

  • RTI Surgical

  • Stemcell Technologies




Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Stem Cell Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Gastrointestinal Diseases
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Musculoskeletal Disorders
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal
Disorders by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 23: World Historic Review for Cardiovascular Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose
Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived
MSCs by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone
Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived
MSCs by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood /
Embryonic Stem Cells by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ for Years 2020
through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem
Cells by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic
Stem Cells by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell
Sources by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ for Years 2020 through 2027 and
% CAGR

Table 35: World Historic Review for Other Cell Sources by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 37: USA Current & Future Analysis for Stem Cell Therapy
by Type - Allogeneic and Autologous - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type -
Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy
by Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy
by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell
Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

CANADA
Table 46: Canada Current & Future Analysis for Stem Cell
Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell
Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell
Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

JAPAN
Table 55: Japan Current & Future Analysis for Stem Cell Therapy
by Type - Allogeneic and Autologous - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy
by Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy
by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

CHINA
Table 64: China Current & Future Analysis for Stem Cell Therapy
by Type - Allogeneic and Autologous - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy
by Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy
by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

EUROPE
Table 73: Europe Current & Future Analysis for Stem Cell
Therapy by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell
Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell
Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell
Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

FRANCE
Table 85: France Current & Future Analysis for Stem Cell
Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell
Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 91: France Current & Future Analysis for Stem Cell
Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for Stem Cell
Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 95: Germany Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Stem Cell
Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 100: Germany Current & Future Analysis for Stem Cell
Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Stem Cell Therapy by
Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived
MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

ITALY
Table 103: Italy Current & Future Analysis for Stem Cell
Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 104: Italy Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Stem Cell Therapy by
Type - Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Stem Cell
Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 109: Italy Current & Future Analysis for Stem Cell
Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 110: Italy Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 111: Italy 15-Year Perspective for Stem Cell Therapy by
Cell Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 112: UK Current & Future Analysis for Stem Cell Therapy
by Type - Allogeneic and Autologous - Independent Analysis of
Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Stem Cell Therapy by Type -
Allogeneic and Autologous Markets - Independent Analysis of
Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Stem Cell Therapy by Type -
Percentage Breakdown of Value Sales for Allogeneic and
Autologous for the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Stem Cell Therapy
by Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases - Independent Analysis of Annual Sales in US$ for the
Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Stem Cell Therapy by
Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Stem Cell Therapy by
Application - Percentage Breakdown of Value Sales for
Gastrointestinal Diseases, Other Applications, Musculoskeletal
Disorders, Wounds & Injuries and Cardiovascular Diseases for
the Years 2012, 2020 & 2027

Table 118: UK Current & Future Analysis for Stem Cell Therapy
by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Stem Cell Therapy by Cell
Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs,
Cord Blood / Embryonic Stem Cells and Other Cell Sources
Markets - Independent Analysis of Annual Sales in US$ for Years
2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Stem Cell Therapy by Cell
Source - Percentage Breakdown of Value Sales for Adipose
Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood /
Embryonic Stem Cells and Other Cell Sources for the Years 2012,
2020 & 2027

REST OF EUROPE
Table 121: Rest of Europe Current & Future Analysis for Stem
Cell Therapy by Type - Allogeneic and Autologous - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027
and % CAGR

Table 122: Rest of Europe Historic Review for Stem Cell Therapy
by Type - Allogeneic and Autologous Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019 and
% CAGR

Table 123: Rest of Europe 15-Year Perspective for Stem Cell
Therapy by Type - Percentage Breakdown of Value Sales for
Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 124: Rest of Europe Current & Future Analysis for Stem
Cell Therapy by Application - Gastrointestinal Diseases, Other
Applications, Musculoskeletal Disorders, Wounds & Injuries and
Cardiovascular Diseases - Independent Analysis of Annual Sales
in US$ for the Years 2020 through 2027 and % CAGR

Table 125: Rest of Europe Historic Review for Stem Cell Therapy
by Application - Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019 and % CAGR

Table 126: Rest of Europe 15-Year Perspective for Stem Cell
Therapy by Application - Percentage Breakdown of Value Sales
for Gastrointestinal Diseases, Other Applications,
Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular
Diseases for the Years 2012, 2020 & 2027

Table 127: Rest of Europe Current & Future Analysis for Stem
Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources - Independent Analysis of Annual Sales in
US$ for the Years 2020 through 2027 and % CAGR

Table 128: Rest of Europe Historic Review for Stem Cell Therapy
by Cell Source - Adipose Tissue-Derived MSCs, Bone
Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and
Other Cell Sources Markets - Independent Analysis of Annual
Sales in US$ for Years 2012 through 2019 and % CAGR

Table 129: Rest of Europe 15-Year Perspective for Stem Cell
Therapy by Cell Source - Percentage Breakdown of Value Sales
for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting